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Abstract
The surface proteins of human influenza A viruses experience positive selection to escape both human immunity and, more
recently, antiviral drug treatments. In bacteria and viruses, immune-escape and drug-resistant phenotypes often appear
through a combination of several mutations that have epistatic effects on pathogen fitness. However, the extent and
structure of epistasis in influenza viral proteins have not been systematically investigated. Here, we develop a novel
statistical method to detect positive epistasis between pairs of sites in a protein, based on the observed temporal patterns
of sequence evolution. The method rests on the simple idea that a substitution at one site should rapidly follow a
substitution at another site if the sites are positively epistatic. We apply this method to the surface proteins hemagglutinin
and neuraminidase of influenza A virus subtypes H3N2 and H1N1. Compared to a non-epistatic null distribution, we detect
substantial amounts of epistasis and determine the identities of putatively epistatic pairs of sites. In particular, using
sequence data alone, our method identifies epistatic interactions between specific sites in neuraminidase that have recently
been demonstrated, in vitro, to confer resistance to the drug oseltamivir; these epistatic interactions are responsible for
widespread drug resistance among H1N1 viruses circulating today. This experimental validation demonstrates the
predictive power of our method to identify epistatic sites of importance for viral adaptation and public health. We conclude
that epistasis plays a large role in shaping the molecular evolution of influenza viruses. In particular, sites with dN=dSv1,
which would normally not be identified as positively selected, can facilitate viral adaptation through epistatic interactions
with their partner sites. The knowledge of specific interactions among sites in influenza proteins may help us to predict the
course of antigenic evolution and, consequently, to select more appropriate vaccines and drugs.
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Introduction
Influenza A is among the most extensively studied viruses,
owing to its importance as a human pathogen [1–6]. With a large,
public database of genetic sequences, influenza viruses also offer a
model system for studying molecular evolution in general. The
evolution of influenza viruses is characterized by frequent
reassortment events within subtypes [3,7] as well as high rates of
amino-acid substitutions in the viral surface proteins hemaggluti-
nin (HA) and neuraminidase (NA) [8–10]. Such high evolutionary
rates reflect both the poor fidelity of the viral polymerase [10], and
the strong selection pressures to evade the human immunity
[8,9,11–13] and, more recently, to develop drug resistance [14–
16].
Numerous experimental studies and statistical analyses of
genetic and antigenic data have identified sets of residues in HA
and NA proteins, the so called epitopes, that are bound by human
antibodies [17–20]. As a consequence, the epitopic sites tend to
evolve especially quickly, in order to evade immunity [8,21,22].
Moreover, several recent studies have suggested lists of amino
acids at specific residues in HA that evolved under positive
selection over the past 40 years [23–25].
In addition to escaping human antibodies, several other
selective forces act on hemagglutinin. As with any functional
protein, HA must maintain its stability and its function – namely,
to bind the sialic acid receptor of host cells and subsequently
mediate membrane fusion [17,18,20,26]. Thus, antibody escape
mutations must not compromise these properties. Yet, numerous
studies of protein evolution in vitro [27–29] as well as studies in
bacteria [30] and viruses [20,31,32] have shown that beneficial
mutations are often pleiotropic: in addition to their original
beneficial effect, they cause some, usually negative, side effects on
other protein properties, such as stability [28,33]. These negative
effects can typically be alleviated or compensated by other
mutations, making certain combinations of mutations substantially
more beneficial than single mutations alone [34,35]. This
phenomenon is known as positive epistasis between mutations
[36]. Epistasis can also be negative, if a combination of mutations
confers a smaller fitness gain than would be expected under
additive effects of the individual mutations [36].
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[30,40,41], and viruses [31,34,35,42], and it plays an important
role in the evolution of immune escape and drug resistance in
various pathogens [35,43–46] including influenza [16,32]. Sur-
prisingly, the extent of epistatic interactions in influenza proteins
has not been systematically quantified or utilized. Yet, the
knowledge of such interactions might provide a powerful tool for
predicting future antigenically important substitutions and,
consequently, for selecting better vaccine strains.
Numerous methods have been developed for detecting epistasis
between mutations, based on sampled genetic sequences [47].
Early methods were based on the idea that co-evolving pairs of
sites in a protein should leave a typical signature in a sequence
alignment, which can be detected using quantities such as mutual
information [48–50]. However, such methods ignore the phylo-
genetic relationships among sequences and so are justified only if
the divergence times between samples are very large [51]. Various
corrections for the phylogenetic non-independence have been
proposed [52–54], and their performance has been shown to be
satisfactory in some cases [55–57]. Nevertheless, methods that
explicitly take account of the phylogeny are preferable [58].
Several such methods have been proposed recently [42,59–66].
Most of them attempt to detect unusually frequent co-occurrences
of substitutions at pairs of sites on individual branches of the
phylogeny. This approach is conservative since it detects only
those positively epistatic pairs of sites for which a mutation at one
site increases the beneficial effect of a mutation at the second site
so dramatically that one mutation could not fix without the other
one [42]. Such strong epistasis can occur, for example, when one
mutation confers a strongly deleterious effect that is compensated
by a second mutation. However, a mutation at one site in a protein
may lead to only a moderate increase in the beneficial effect of a
mutation at another site, so that the latter substitution occurs at an
accelerated rate, but it does not necessarily appear exclusively on
the same branch of the phylogeny [59,62,64,65]. In other words,
substitutions at positively epistatic pairs of sites are likely to be
temporally clustered [67]. In this paper, we exploit this idea to
design an ‘‘epistasis statistic’’ that allows us to detect a broad class
of epistatically interacting pairs of sites.
In essence, for each ordered pair of sites in a protein we measure
the amount of phylogenetic time that typically elapses between a
substitution at the first site and a subsequent substitution at its
partner site. The epistasis statistic is defined as a decreasing
function of this time interval. Thus, pairs in which the substitution
rate at the second site tends to be increased after a substitution at
the first site will have a larger value of the statistic. We obtain the
null distribution of this statistic for all pairs simultaneously, by
randomly shuffling the identities of substitutions on the phylogeny.
We show that the number of site pairs in the surface proteins of the
human influenza A/H3N2 virus with large values of the epistasis
statistic significantly exceeds the null expectation—thus, influenza
surface proteins evolve under substantial positive epistasis. We
characterize the epistatically interacting sites we have inferred in
terms of their overall patterns of evolution, protein locations, and
functional significance. For type-1 neuraminidase, we compare the
identities of the epistatic sites we have inferred with those that have
been experimentally verified. We discuss the implications of our
results both for practical issues surrounding influenza’s antigenic
drift and drug resistance, and for broader issues surrounding
protein evolution in general.
Results
Identifying epistatic pairs of sites
We reconstructed the phylogenetic trees for HA and NA
proteins (subtypes H3N2 and H1N1) and inferred the nucleotide
sequences at internal nodes by maximum likelihood as described
in ‘‘Materials and Methods’’. In order to detect pairs of codon sites
in a protein that have evolved under positive epistasis we used the
‘‘epistasis statistic’’ described in ‘‘Materials and Methods’’.
Briefly, the epistasis statistic considers an ordered pair of sites,
the first of which is called the ‘‘leading site’’ and the second is
called the ‘‘trailing site’’. The epistasis statistic tends to be large for
pairs of sites (i,j) in which a non-synonymous substitution at site j
tends to quickly follow a non-synonymous substitution at site i, and
for which substitutions at the trailing site occur in multiple lineages
(see schematic in Figure 1). We measure time between a pair of
non-synonymous substitutions as the number of synonymous
substitutions that occur between them. Since we are interested in
positive epistasis and would like to detect only those pairs of
substitutions in which the second substitution is beneficial, we
excluded all substitutions at terminal branches, because many such
substitutions are likely to be deleterious. We also discarded all sites
that experienced fewer than two substitutions at the internal
branches (Table 1).
The epistasis statistic depends on the parameter t that sets the
timescale over which substitutions contribute information. Pairs of
substitutions that are separated by times much shorter than t
contribute significantly to the epistasis statistic, whereas pairs of
substitutions that are separated by times much longer than t do
not. We set t to be equal to the average time StnsT, measured in
the number of synonymous substitutions, that elapses between two
non-synonymous substitutions randomly sampled from a phylog-
eny (see Text S1 and Table 1). For each phylogeny (H1, N1, H3,
and N2) and its corresponding value of t, we computed the
epistasis statistic for all qualifying ordered pairs of sites and, for
each such pair, we computed the distribution of the epistasis
statistic under the non-epistatic null hypothesis (see ‘‘Materials and
Methods’’ for details). We then selected all pairs of sites whose
nominal P-value was smaller or equal to 0.01. In H3, we identified
333 site pairs with a nominally significant epistasis statistic; we
identified 225 such pairs in H1, 205 such pairs in N1, and 188
Author Summary
Epistasis describes non-additive interactions among ge-
netic sites: the consequence of a mutation at one site may
depend on the status of the genome at other sites. In an
extreme case, a mutation may have no effect if it arises on
one genetic background, but a strong effect on another
background. Epistatic mutations in viruses and bacteria
that live under severe conditions, such as antibiotic
treatments or immune pressure, often allow pathogens
to develop drug resistance or escape the immune system.
In this paper we develop a new phylogenetic method for
detecting epistasis, and we apply this method to the
surface proteins of the influenza A virus, which are
important targets of the immune system and drug
treatments. The authors identify and characterize hun-
dreds of epistatic mutations in these proteins. Among
those identified, we find the specific epistatic mutations
that were recently shown, experimentally, to confer
resistance to the drug Tamiflu. The results of this study
may help to predict the course of influenza’s antigenic
evolution and to select more appropriate vaccines and
drugs.
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site pairs in HA and NA are shown in Figure 2 and Figure 3.
We computed the false discovery rate (FDR) as well as the
overall P-value for the observed number of significant pairs (see
‘‘Materials and Methods’’). Although the FDR in all proteins was
high, around 60%, the observed number of nominally significant
pairs was much larger than would be expected by chance
(pv0:015, see Table 1). Reducing the nominal P-value cutoff
somewhat reduced the FDR but also disproportionately reduced
the number of inferred positives (see Figure S1).
We tested the sensitivity of our method with respect to the
choice of the timescale parameter, t in the range from t~1 to
t~200, as well as to uncertainty in phylogeny and internal node
reconstruction. The results remained qualitatively similar to those
reported here (see Text S1, Figure S2, and Table S4). As a
negative control, we performed 100 simulations in which sites
evolved independently (i.e. without epistasis) along a given
phylogenetic tree (see ‘‘Materials and Methods’’). In 52 out of
100 simulations, the number of significant pairs at the P-value
cutoff 0.01 was smaller than expected, in 47 cases this number was
larger that expected, but not significantly so. In only one
simulation out of 100 was this number larger than expected and
significant (Pv0:01). We are therefore confident that our method
indeed detects epistatic pairs of sites, and it does not systematically
report more false positives than our FDR computation indicates.
Characterizing epistatic pairs of sites
Having obtained a list of pairs of sites with putative epistatic
interactions (Table S1, Figure 2 and Figure 3), we inspected the
properties of these pairs, compared to an appropriate null set. In
particular, we compared the true, epistatic pairs to the pairs that
had appeared as nominally significant in the 400 ‘‘fake data sets’’
Figure 1. Detecting positive epistasis between mutations at
two sites, i and j. The epistasis statistic is defined in terms of the total
time elapsed between all pairs of consecutive substitutions at sites i
and j (see ‘‘Materials and Methods’’). In this schematic figure,
substitutions at sites i and j are denoted by red and blue circles,
respectively. Substitutions (A,C) and (B,D) form consecutive pairs.
Substitutions (B,C) are not consecutive because they occur on different
lineages. Substitutions (A,D) are not consecutive because substitution
B at site i occurs between them.
doi:10.1371/journal.pgen.1001301.g001
Table 1. Summary of data used in our analysis.
H3N2 H1N1
H3 N2 H1 N1
number of sequences 2149 2339 1219 1836
PDB accession number 2VIU 1NN2 1RUZ 3BEQ
protein length 566 469 565 470
number of epitopic sites
1 131 45 – –
sites considered 141 111 115 113
pairs considered 19740 12210 13110 12656
t used 63 54 78 60
pairs significant at 0.01 (exp) 196 122 132 122
pairs significant at 0.01 (obs) 333 188 225 205
FDR, % 58.8 64.8 58.7 59.3
P-value
2 v0:01 0:015 v0:01 v0:01
1epitopic sites are taken from [8,17] for H3, from [8,19,20] for N2;
2P-value is for the number of nominally significant pairs. FDR stands for ‘‘false
discovery rate’’ (see ‘‘Materials and Methods’’).
doi:10.1371/journal.pgen.1001301.t001
Figure 2. Phylogenetic tree of HA (subtype H3) illustrating a
putatively epistatic interaction between sites 391 (red circles)
and 73 (blue circles). Site 391 is not in an epitope, dN=dS~0:47; site
73 is epitope E, dN=dS~0:72. Only substitutions at internal nodes are
displayed. Branch lengths are equal to the total number of substitutions
across all sites. Vertical bars show the approximate years in which the
sequences were isolated. Substitutions C, D, E, and F at site 73 closely
follow substitution A at site 391, leading to a highly significant value of
the epistasis statistic (E63(391,73)~3:48, nominal P-valuev10{4). As a
result, the ordered pair of sites (391, 73) is detected as epistatic by our
method. At the same time, only a single substitution, B, at site 391
follows substitution F at site 73 – and only after a long period of time –
resulting in a low value of the epistasis statistic for the inverse pair
(E63(73,391)~1:20, nominal P-value~0:18). Therefore, the ordered pair
of sites (73,391) is not detected as epistatic by our method.
doi:10.1371/journal.pgen.1001301.g002
Epistasis in Influenza Surface Proteins
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we asked whether the pairs that we detected as epistatic differed
systematically from the false positive pairs. We investigated three
types of properties: the average dN/dS value at epistatically
interacting sites, their location in the protein with respect to known
epitopes (for H3N2 only), and the distances between interacting
sites. For comparison of physical and linear distances we also
excluded sites that were not present in the resolved crystal
structure (see ‘‘Materials and Methods’’). The results are
summarized in Table 2 and Table 3, and discussed below.
The dN/dS values at the leading sites among the putative
epistatic pairs were not significantly larger, on average, than at the
leading sites among pairs identified under permutation. However,
the average dN/dS value at the leading sites was less than one,
which is usually interpreted as evidence of purifying selection.
Therefore, without an analysis of epistasis, many of the leading
sites would not have been identified as experiencing positive
selection, even though they may play a critical role in facilitating
adaptation in co-ordination with substitutions at their partner sites.
By contrast to the leading sites, the dN/dS values at the trailing
sites were significantly larger than the null expectation, and they
exceeded one on average (with the exception of N1). Thus, the
trailing sites exhibit the characteristic signature of positive selection
[68], even though the positive selection they experience was likely
made possible (or, at least, more likely) by preceding substitutions
at their corresponding leading sites. In other words, many of the
positively selected substitutions that have occurred in HA and NA
may have been facilitated by previous substitutions at epistatically
interacting sites. In previous work, we have identified 25 sites in
H3 at which certain specific amino acids evolved under directional
positive selection [25]. Interestingly, 22 of these sites appear to be
involved in epistatic interactions: 10 sites appear as leading sites, 7
sites appear as trailing, and 5 sites appear as both.
We also studied the location of epistatic sites with respect to the
known antigenic regions of the influenza surface proteins, for H3
and N2. In both proteins, the leading site in an epistatic pair was
more likely to fall within an antigenic epitope than under the null
expectation (and significantly so in H3). The trailing site was
slightly more likely to fall outside of known epitopes, despite the
fact that the dN/dS ratio was typically greater than 1 at such sites.
Thus, pairs of sites in which the leading site was in an epitope and
the trailing site was not in an epitope, were typically overrepre-
sented (although not significantly so). This suggests that the leading
sites may often be directly involved in antigenic escape and the
trailing sites may subsequently compensate for deleterious (e.g.
destabilizing) side effects of the initial mutation. In some cases,
however, both the leading and trailing sites of an epistatic pair fall
within epitopes (47% of pairs in H3, 9% of pairs in N2). In such
cases, for H3, the leading and trailing sites were significantly more
likely to fall in different epitopes from each other, than expected –
suggesting that substitutions across multiple epitopes may be
particularly important for antigenic escape, at least in hemagglu-
tinin of the H3 subtype. This observation reflects the widely held
belief that antigenic change in hemagglutinin typically requires
multiple substitutions spread across multiple epitopes [21,26].
How far apart are the leading and trailing sites of epistatic pairs?
Surprisingly, neither the average linear (sequence) distance nor the
physical distance between the leading and the trailing sites in an
epistatically interacting pair was significantly smaller than would
be expected among false positive pairs.
Finally, we investigated the timing of consecutive substitutions
at the leading and trailing sites in epistatic pairs. On average, both
across pairs and across consecutive substitutions, a substitution at a
leading site in H3 was followed by a consecutive substitution at its
corresponding trailing site 3.7 years later (see Text S1 for details).
Similarly, in H1 the mean time between consecutive substitutions
was 5.8 years; 4.4 years in N1; and 4.2 years in N2. In all cases, the
mean time between consecutive substitutions exceeds two years –
which suggests that the observation of a substitution at the leading
site of a known epistatic pair may provide useful predictive value
for anticipating a subsequent substitution at its corresponding
trailing site, within the time-frame required for selecting a seasonal
vaccine strain [69].
Epistasis and the evolution of oseltamivir resistance
Our analyses of substitution patterns suggest that positive
epistasis is prevalent among sites in HA and NA. However, it is
important to verify experimentally that the identified pairs of sites
indeed show non-additive fitness effects. Fortunately, such
verification has recently been performed for two specific pairs of
sites in type-1 neuraminidase.
Currently circulating variants of the seasonal H1N1 subtype are
resistant to the drug oseltamivir, which inhibits neuraminidase
[15]. Resistance to this drug is conferred by the mutation
His?Tyr at site 275, which is referred to as the ‘‘H274Y’’
mutation in the literature [15]. However, this mutation is known
to be strongly deleterious in the absence of the drug [70].
Recently, Bloom et al. demonstrated that mutations R222Q and
V234M restore the drug-resistant mutant’s fitness in vitro [16], for
seasonal H1N1. They also observed that mutations R222Q and
V234M were fixed in the seasonal H1N1 population prior to the
emergence of the H275Y mutation, and thus they likely acted as
epistatic ‘‘permissive mutations’’ for the emergence of drug
resistance in competent viruses.
Figure 3. Phylogenetic tree of NA (subtype N1) illustrating a
putatively epistatic interaction between the leading site 344
(red circles) and the trailing site 275 (blue circles). Other
notations are as in Figure 2.
doi:10.1371/journal.pgen.1001301.g003
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sequence evolution alone, is remarkably concordant with the
experimental findings of Bloom et al. In particular, our analysis
indicates that sites 222 and 234 interact strongly with site 275 (see
Table S1). Moreover, among the top 10 most significantly epistatic
pairs in N1 there are 6 other pairs that involve the drug-resistance
site 275 as the trailing site; the leading sites in these pairs are 214,
287, 329, 354, 382, and 344. In all cases the subsequent mutation
at site 275 is His?Tyr. Therefore, aside from sites 222 and 234,
our analysis predicts that these six additional sites may be
permissive mutations that, in combination with H275Y, produce
competent, drug-resistant viruses. Although no epistasis between
two of these sites (214 and 382) and site 275 was found
experimentally [16], one of the mutations (D344N) has subse-
quently been shown to help counteract the decrease in total
surface-expressed activity associated with the mutant neuramini-
dase ([71] and Jesse Bloom, personal communication), and it,
along with 224 and 234, may have played a role in the emergence
of oseltamivir resistance in seasonal H1N1 viruses before 2009.
Although further experimental validation is required, the
remarkable concordance between our statistical inferences and
experimentally verified epistatic interactions [16] suggests that
patterns of sequence evolution contain extremely useful informa-
tion about a protein’s fitness landscape. In the case of oseltamivir
resistance, this information is highly specific and of significant
import to public health.
Table 2. Characterization of epistatic pairs in subtype H3N2 surface proteins, compared to expectations for randomly chosen
pairs.
H3 N2
exp obs exp obs
leading site average dN/dS 0:88 0:91 (ns) 0:84 0:70 (ns)
fraction ept 0:59 0:82
* 0:26 0:43 (ns)
trailing site average dN/dS 0:86 1:12
** 0:83 1:29
**
fraction ept 0:58 0:54 (ns) 0:27 0:20 (ns)
fraction of pairs both npt 0:17 0:11 (ns) 0:54 0:46 (ns)
(npt, ept) 0:24 0:07
* 0:20 0:12 (ns)
(ept, npt) 0:25 0:35 (ns) 0:19 0:34 (ns)
same ept 0:07 0:07 (ns) 0:03 0:03 (ns)
diff. ept 0:27 0:40
* 0:04 0:06 (ns)
time btw. consec. subst. (in syn subst) mean N/A 14.71 N/A 13.82
std N/A 16.76 N/A 15.72
time btw. consec. subst. (in years) mean N/A 3.68 N/A 4.22
std N/A 4.20 N/A 4.80
average distance
1 linear 135:51 1 4 :3 (ns) 124:3 124:3 (ns)
physical, A ˚ 43:13 8 :9 (ns) 28:62 8 :2 (ns)
P-values are obtained from two-tailed tests, except for the last two rows which report one-sided tests regarding distances between sites. Single and double asterisks
denote significance at 0.05 and 0.01 level, respectively; ‘‘ns’’, ‘‘ept’’, ‘‘npt’’, ‘‘obs’’, ‘‘exp’’, and ‘‘N/A’’ denote not significant, epitopic, non-epitopic, observed, expected,
and not applicable respectively.
1Average distances are computed only over those significant pairs in which both residues are present in the crystal structure (see ‘‘Materials and Methods’’).
doi:10.1371/journal.pgen.1001301.t002
Table 3. Characterization of epistatic pairs in subtype H1N1 surface proteins, compared to expectations for randomly chosen
pairs.
H1 N1
exp obs exp obs
leading site average dN/dS 0:94 0:89 (ns) 0:75 0:91 (ns)
trailing site average dN/dS 0:93 1:90
** 0:73 0:76 (ns)
time btw. consec. subst. (in syn subst) mean N/A 25.56 N/A 14.75
std N/A 28.64 N/A 17.09
time btw. consec. subst. (in years) mean N/A 5.80 N/A 4.40
std N/A 6.50 N/A 5.10
average distance linear 117:4 106:9 (ns) 130:11 0 8 :6 (ns)
physical, A ˚ 37:53 7 :6 (ns) 27:72 8 :6 (ns)
Notations as in Table 2.
doi:10.1371/journal.pgen.1001301.t003
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advance of the drug’s widespread introduction. Moreover, this
prior knowledge was used by Bloom et al. [16] to focus their
experimental search for an epistatic partner to site 275.
Nonetheless, our method of identifying epistatic pairs from
sequence data implicates site 275 – without any prior knowledge
of its role in drug resistance – as extremely important in the
adaptive evolution of N1, especially in combination with sites 222,
234, and six other leading sites (Table S1). This demonstrates the
practical, predictive power of our method for inferring the specific,
epistatic interactions that shape viral adaptation. Thus, our
method may, in the future, help us identify sites important for
drug resistance or antigenic drift, even when no prior experimental
data are available.
Finally, we note that our analysis implicates sites 222 and 234,
which have been verified as important epistatic partners of the
oseltamivir resistance site 275, as significant epistatic leading sites
even when we restrict our data set to those viral isolates prior to
the introduction of oseltamivir. In particular, based on sequence
data prior to 2001, our method identifies sites 222 and 234 as
participating in epistatic interactions with sites other than 275 (see
Table S1). Thus, sites 222 and 234 may be structurally important
and experience epistatic interactions even in the absence of
selection for oseltamivir resistance.
Discussion
We have developed a statistical method to detect positive
epistasis between pairs of sites in a protein, based on patterns of
thoroughly-sampled sequence variation. The essential idea
underlying this method is simple: a substitution at one site should
rapidly follow a substitution at another site if the sites interact
epistatically. We applied this method to identify putative epistatic
pairs in the influenza surface proteins hemagglutinin and
neuraminidase, and we found a highly significant number of
interacting pairs. We characterized the properties of the leading
and trailing sites identified as epistatic. Finally, we validated our
approach by comparison to experimentally verified epistatic
interactions in neuraminidase, with significant implications for
public health.
This study sheds some light on methodological and empirical
questions in molecular evolution generally, as well as practical
questions about influenza viral evolution in particular. Method-
ologically, it is instructive to compare our approach to identifying
epistasis with other techniques in the literature. Over very long
timescales, interacting sites in a protein have been identified by
inspecting multiple sequence alignments, ignoring the phyloge-
netic relationship among the sequences being compared. Such an
approach is justifiable over timescales so long that each site may be
treated independently, and indeed it has proven successful at
identifying epistasis in proteins conserved across all domains of life
[51]. However, such techniques are not justified for shorter
timescales, because correlations between sites may arise simply as
the result of linkage and shared ancestry [58]. Although techniques
exist to control for phylogeny in such tests [52–54], it is preferable
to leverage the phylogeny in the design of a more powerful statistic
for epistasis – which is the approach we have taken here.
Even among the techniques that account for phylogeny,
methods differ in their power to detect epistasis. Some methods
will be more powerful in some contexts, and others in other
contexts – depending upon the structure of epistasis among sites,
the selection coefficients involved, and the density of sampling.
Most existing methods that utilize phylogenetic information
assume that epistatic substitutions will co-occur along the same
branch of the phylogeny [42,60,63,64]. This assumption will not
always be met, however, if the selective advantage conferred by a
substitution at the trailing site is only moderate; in such cases,
substitutions at trailing sites will occur at an accelerated rate but
they may likely fall on subsequent branches in the phylogeny. To
demonstrate this point, we applied the method of Poon et al [64],
implemented in the HyPhy package [72], to the same data set of
influenza sequences. That method detected 4 to 10 times fewer
epistatically interacting pairs of sites than our method did, at the
same false discovery rate (see Text S1 and Tables S2 and S3).
Importantly, the method by Poon et al. failed to detect epistatic
interactions between sites 222 and 234 and the drug-resistance site
275 in neuraminidase subtype N1, even though those pairs were
highly ranked by our method and those epistatic interactions were
confirmed experimentally. Although a thorough comparison
between various existing methods is beyond the scope of this
paper, we believe that the additional power of our method to
detect epistasis in the influenza data arises because we allow for
time lags between substitutions at interacting sites.
The epistasis statistic developed here is admittedly ad-hoc,
compared to systematic, likelihood-based methods for jointly
inferring phylogeny and epistasis under Markov substitution
models [73–75]. At the same time, the vast dimensionality
associated with substitution models incorporating pairwise epista-
sis, of order (20L)
2 for a sequence of length L, is daunting;
whereas the frequentist statistic defined here seems to perform
quite well. The strong performance of our approach likely arises
from our ability to infer ancestral states reliably, due to the high-
resolution sampling of influenza sequences.
Our method has several important shortcomings. One draw-
back is that it requires a large number of substitutions per site in
order to discriminate between truly interacting site pairs and pairs
that sustain substitutions in close succession just by chance.
Moreover, even if the protein evolves rapidly, as influenza surface
proteins do, the false discovery rate is still very high. Our method
will likely perform much worse for proteins that evolve slowly or
have been sampled sparsely.
Two other concerns are problematic for our approach, as well
as most other methods of detecting epistasis from phylogenetic
data. Such approaches generally suffer from the inability to weed
out spuriously epistatic pairs, which leads to high false discovery
rates. There are at least two sources of spuriously significant pairs:
hitchhiking and coordinated temporal variation in selection
pressures across sites. Imagine, for example, that sites A and B
interact epistatically and that multiple substitutions at site B in
independent lineages rapidly follow a single substitution at site A.
Then site pair (A,B) would be detected by our method. However,
if the variant that carries the leading mutation at site A also, by
chance, happens to carry a mutation at site C (which is not
epistatic with B), then mutation C hitchhikes to fixation together
with mutation A and so the site pair (C,B) may also be detected as
epistatic. In fact, mutation at site C may be advantageous while
mutation at site A may be a neutral or slightly deleterious
mutation that hitchhikes to fixation together with C, but then
‘‘permits’’ the beneficial mutation at site B. It may be possible to
reduce the false discovery rate by designing statistics that consider
only those site pairs for which consecutive substitutions involve
multiple independent substitutions at the leading site as well as the
trailing site.
Coordinated temporal variation in selection pressures across
sites is another source of potential false positives under this and
other tests of epistasis. Consider, for example, sites 391 and 73 in
H3 illustrated in Figure 2. Substitutions at site 73 appear to quickly
follow substitutions at site 391 in the early 1990’s. Apart from
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explained if both sites independently experienced positive selection
during this time period, and otherwise negative selection.
However, if this explanation were the dominant one for the
observed clustering of substitutions, then, for each nominally
significant ordered pair of sites, we would expect its inverse pair
also to be nominally significant, on average. Yet, we do not find a
single nominally significant pair whose inverse pair is also
nominally significant, even though consecutive substitutions do
occur in the direct and reverse order (see for example, Figure 2
and Table S1). It is unlikely that this observation is caused by
insufficient sampling. Indeed, in H3, there are typically more than
6 substitutions (at internal branches) at either a leading or trailing
site in an identified epistatic pair, and similarly for the other
proteins. Moreover, many sites appear in our lists as both leading
and trailing. Thus, leading and trailing sites exhibit similar number
and pattern of substitutions, and there is plenty of power to detect
a significant epistasis statistic in both directions. This suggests that
the excess of significant pairs we observe is likely caused by
epistasis, rather than coordinated temporal variation in selection
pressures.
Another shortcoming of our method is that it aims to detect
epistasis only between pairs of sites, whereas interactions among
residues in a protein are certainly more complex. This may be a
cause of our large false discovery rate. Imagine, for example, three
sites, A, B, and C, such that pairs (A,B) and (B,C) interact
epistatically, but the pair (A,C) does not. If substitutions at site B
quickly follow substitutions at site A and if substitutions at site C
quickly follow substitutions at site B, our method may detect the
pair (A,C) as epistatic, even though there is no direct epistatic
interaction between these sites. Indeed, in our list of putatively
epistatic pairs, we find 133 of such ‘‘circular’’ triplets in H3, 41
triplets in N2, 81 triplets in H1, and 71 triplets in N1. In order to
discriminate truly epistatically interacting site pairs from spurious
pairs, it may be possible to modify the Bayesian graphical models
recently used for detecting epistasis in HIV [64,66] to incorporate
a time lag between consecutive substitutions.
Finally, although our method detects epistatic interactions
between pairs of sites, it does not determine which specific
mutations at those sites were epistatic. Extending our permutation
technique to incorporate the information about specific mutations
may prove difficult, but in many cases it is unnecessary. Often we
can a posteriori identify the specific mutations that led to a
significant value of the epistasis statistic for a pair of sites. For
example, the drug-resistance site 275 is identified as trailing with
many leading sites in N1 (see Table S1), but the specific
substitutions at site 275 are all in fact identical: H275Y.
Methodological issues aside, our results on epistasis in HA and
NA have several important practical implications for our
understanding of influenza evolution. We have demonstrated that
our method reliably infers a critically important oseltamivir
resistance site, as well as the associated leading sites at which
initial mutations are required for the production of a viable, drug-
resistant virus. Remarkably, we can identify some of the leading
sites (222 and 234) even when restricted to sequence data prior to
the introduction of the drug. This degree of specificity and
accuracy may prove helpful in preparing for resistance to other
drugs that may be developed, or in predicting the emergence of
oseltamivir resistance in the recent type-1 swine neuraminidase
responsible for the 2009-10 influenza pandemic.
In addition to NA, we have also detected substantial amounts of
epistasis in HA, including in the known epitopes, likely associated
with antigenic drift. Knowledge of specific pairs of sites that
interact epistatically in HA may improve our ability to predict
future antigenic variants, and thus to calibrate vaccine strain
choices accordingly. Previous studies of HA antigenic evolution
have focused almost exclusively on those sites with the strongest
signatures of positive selection, e.g. elevated dN/dS ratios
[8,21,22]. However, our results suggest that this approach will
inevitably miss many sites of genuine importance to adaptation,
and will implicate others that are not directly involved in antigenic
escape. In particular, we have seen that the leading site of an
epistatic pair often falls within an epitope, but it also often exhibits
dN=dSv1. In contrast, the trailing site typically falls outside of an
epitope and it exhibits significantly elevated dN=dSw1. This
observation appears counter to our expectation that epitopic sites
have elevated dN/dS values and non-epitopic sites have depressed
dN/dS values. However, not all epitopic sites experience elevated
dN/dS values at all times because different epitopes may be
immunodominant at different times [76,77]. Thus, an average
dN/dS value at a site may be well below 1 even if this site
occasionally evolves under strong immune selection [78].
The patterns of epistatic interactions we have detected suggest
the the following speculative model for the evolution of influenza
surface proteins. If an epitope is immunodominant at a certain
period of time, the pressure for antigenic escape is so strong that
the leading site, of antigenic importance, substitutes despite a
negative side-effect (e.g. diminished protein stability or function).
This side-effect is subsequently compensated by a substitution at
another, relatively unconstrained, site, in an epitope or not. It is
possible that such unconstrained sites may act as ‘‘global
suppressors’’, i.e., compensate the destabilizing effects of many
mutations [79,80]. If there is a constant need for compensation
(caused by antigenically important mutations), such compensating
sites will continually evolve under positive selection and will
exhibit dN=dSw1. Under this scenario, the roles of the two sites
would both be misinterpreted by an analysis based on dN/dS
alone that neglects epistasis. In particular, our observations imply
that mutations at sites with dN=dSv1 may sometimes be
extremely important for antigenic adaptation, even though they
have been largely ignored in compilations of antigenically relevant
sites [8,11,21]. Conversely, some mutations at sites with
dN=dSw1 may be unimportant for antigenicity per se, but are
positively selected simply to compensate for prior antigenic escape
mutations with deleterious side effects. Another potential mech-
anism of epistasis in influenza surface proteins could be the
dynamic balance between mutations that simultaneously influence
receptor binding avidity and antigenicity, as suggested recently by
Hensley et al. [81].
Some of the epistatic pairs that we detect consist of an
apparently neutral but ‘‘permissive’’ mutation at the leading site
followed by a highly advantageous mutation at the trailing site,
such as the pair of mutations V234M and H274Y in N1 previously
identified by Bloom et al [16] and also detected by our method
(Table S1). This observation is consistent with the idea that neutral
or nearly neutral substitutions can facilitate adaptation at partner
sites that might not otherwise have been available—a concept that
has received much attention in theoretical studies of adaptation
[82,83] and of influenza evolution in particular [84].
Finally, we have observed that epistatic residues do not tend to
be significantly closer to each other in the folded protein structure
than would be expected by chance – a result that we expect to hold
generally, and which suggests that structural influences on epistasis
are probably not as straightforward as simple proximity of
residues. In the future, it will be important to investigate, by
computation or experiment, whether epistatic partner sites are
compensating for protein stability even if they are distant from
each other in a folded protein structure.
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Data
We downloaded all HA and NA coding region sequences of
human influenza A virus subtypes H1N1 and H3N2 that were
available in the NCBI’s Influenza Virus Resource [85] in June
2010. The amino acid sequences were aligned using Clustal W ver.
1.83 [86] and the alignments were reverse translated using
PAL2NAL [87]. Occasional gaps in the alignments were filled if
more than 70 percent of sequences agreed on the nucleotide at the
gap position; otherwise the sequence with a gap was excluded from
further analysis. To test some aspects of our method, we used a
smaller HA data set (subtype H3N2) which was downloaded in
April 2009. To investigate whether our method detected any of the
known epistatic site pairs in type-1 NA prior to the introduction of
oseltamivir, we also used a truncated data set of N1 sequences with
all sequences isolated subsequent to 2001 removed. All used
alignments are available upon request.
In computing the epistasis statistic we excluded all substitutions
at terminal branches, and we discarded all sites that experienced
fewer than 2 substitutions at the internal branches.
We also downloaded the HA and NA crystal structures from the
RCSB Protein Data Bank. In computing the linear (sequence) and
physical distances between residues we excluded all residues that
were not resolved in the crystal structures. We used the distance
between the alpha-carbon atoms as a proxy for the physical
distance between residues.
Phylogeny reconstruction and substitution mapping
We reconstructed the maximum likelihood phylogenetic trees
for HA and NA using PHYML [88] under the GTR substitution
model with the four-category discrete approximation of the
gamma distribution for the substitution rates. We reconstructed
the nucleotide sequences at the internal nodes of the phylogeny
using maximum likelihood algorithm in PAUP* 4.0b10 [89]. For
each codon site, we identified whether it experienced at least one
synonymous and/or non-synonymous substitution on each branch
of the reconstructed phylogeny. In those rare cases in which a
codon experienced more than one substitution of the same kind
(synonymous or non-synonymous) on a branch, we did not record
the number of substitutions, in order to simplify computations.
The epistasis test statistic
Consider an ordered pair of sites (i,j) in the protein of interest.
In order to detect a positive epistatic interaction for this pair, we
designed a statistic that detects the acceleration of non-synony-
mous substitutions at site j, which we call the trailing site, after the
occurrence of a non-synonymous substitution at site i, which we
call the leading site.
First, we obtained a strict temporal order in which non-
synonymous substitutions at sites i and j occurred on the
phylogenetic tree. Such an order is not actually known if the
phylogeny contains one or more branches on which both sites
have experienced a non-synonymous substitution. We say that
such branches are temporally unresolved with respect to the pair (i,j).
Since we do not know in which order the sites in the pair have
experienced substitutions on a temporally unresolved branch, we
assume that both orders are equiprobable. If there are mij
branches on the phylogenetic tree that are temporally unresolved
with respect to the pair (i,j), there are a total of 2mij equally likely
distinct strict temporal orders of substitutions on the tree with
respect to this pair.
Next, for each strict temporal order of substitutions O
(k)
ij ,
k~1,...,2mij, at sites i and j, we find all pairs of substitutions that
are consecutive along the tree. Substitution B at the trailing site (in
this case j) and substitution A at the leading site (in this case i) form
a consecutive pair p~(A,B) if A has occurred in the lineage ancestral
to B and no other substitution at either site has occurred in the
lineage between them. This notion is illustrated in Figure 1. If
(A,B) is a consecutive pair, we also say that substitution B is
consecutive to substitution A. For each consecutive pair (A,B),
substitution A is called initial and substitution B is called subsequent.
Before defining the epistasis statistic we introduce some
notation. We denote the fact that branch a is ancestral to branch
b by a[b (‘‘a precedes b’’) or by b]a (‘‘b follows a’’); if a and b
denote the same branch, we naturally write a~b. We denote the
number of synonymous substitutions that occurred on branch a by
la. We measure time tp between the initial substitution A and the
subsequent substitution B of a consecutive pair p~(A,B) as the
expected number of synonymous substitutions that occurred
between them. More precisely, if substitutions A and B occurred
on branches a and b respectively, then
tp:t(a,b)~
la=3, if a~b
la=2z
X
c :
a[c[b
lczlb=2, if a[b
8
> <
> :
ð1Þ
The sum in this expression is taken over all branches on the lineage
connecting branches a and b. Note that tp can be zero if no
synonymous substitutions occurred between substitutions A and B.
Let S
(k)
ij denote the set of all consecutive substitution pairs at site
pair (i,j) found on the phylogenetic tree with the order of
substitutions O
(k)
ij . We define the epistasis statistic as
Et(i,j)~
1
2
mij
X 2
mij
k~1
X
p[S(k)
ij
exp {tp=t fg , ð2Þ
where tw0 is a time-scale parameter that we specify in the
‘‘Results’’ section. The choice of an exponential function of tp is
arbitrary. We expect that any monotonic decreasing function of tp
would yield similar results. Note that if mij~0, i.e. if sites i and j
never experience a non-synonymous substitution on the same
branch, the strict temporal order of substitutions with respect to
the ordered pair (i,j) is unique. In this simple case, the epistasis
statistic is equivalent to
Et(i,j)~
X
p[S(1)
ij
exp {tp=t fg :
If we take the time-scale parameter t to be infinite, the statistic
E?(i,j) simply equals the number of consecutive substitutions for
the ordered pair (i,j). We also define Et(i,j):0 if all sets
S
(k)
ij , k~1,...,2mij are empty for the pair (i,j). In other words, the
epistasis statistic is zero for pairs of sites that never experience
consecutive substitutions.
The value of the epistasis statistic Et(i,j) is large if substitutions
at the trailing site often follow substitutions at the leading site and
if the time-lag between initial substitutions at the leading site and
subsequent substitutions at the trailing site is typically small
(compared to t). We therefore expect that pairs of sites that evolve
under positive epistasis will have a larger value of the epistasis
statistic.
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If there were no epistatic interactions between sites and no
temporal variation in selection pressures then we would expect the
non-synonymous substitutions at each site to be distributed
randomly on the phylogenetic tree. In order to obtain the
distributions of the epistasis statistic under this null hypothesis for
all ordered pairs of sites, we utilize the following straightforward
permutation procedure. We shuffle all non-synonymous substitu-
tions on the phylogenetic tree while keeping two sets of marginal
quantities preserved: (a) for each branch of the phylogeny, we
preserve the number of non-synonymous substitutions that
occurred on that branch and (b) for each site, we preserve the
total number of non-synonymous substitutions that occurred at
that site on the tree. Condition (a) ensures that any possible
temporal biases in the sampling of viral isolates, which would
apply equally to all sites, are preserved in the null distribution.
Condition (b) ensures that the overall selective constraint on each
site is preserved. Synonymous substitutions are unaffected by this
shuffling procedure.
Although this permutation procedure is conceptually simple, its
computational implementation is challenging. A priori, it is
unclear how to efficiently sample the space of possible substitution
configurations while preserving the aforementioned marginals.
This problem can be rephrased as follows. We can represent the
phylogenetic tree with non-synonymous substitutions as an M|N
matrix, where M is the number of branches on the phylogeny and
N is the number of sites, so that each cell in the matrix is either 1
or 0 depending on whether or not the given site experienced a
non-synonymous substitution on the given branch. Thus, we
would like to randomly permute the entries of this matrix while
preserving the row and column sums. This problem is equivalent
to the problem of obtaining the null distribution for the matrix of
associations between individuals across a set of observations, which
has been extensively studied in the ecology literature [90–92]. The
method typically employed in ecology to sample the space of
matrices that satisfy the constraint on the marginals is called the
‘‘swap method’’ and is based on the idea of swapping the entries of
certain specific 2|2 submatrices in a way that does not violate the
constraints. This method, although computationally efficient,
generates matrices that are not independent [91]. An alternative
‘‘fill method’’ permutes the matrix entries and simply discards
those resulting matrices that do not satisfy the constraints [92].
This method can be prohibitively computationally expensive if
many matrices are discarded, but it guarantees independent
sampling.
We employed the ‘‘fill method’’ and found that only about
between 0.05% and 5% of matrices are accepted, yet this did not
present a serious computational limitation. We generated 104 valid
permutations per protein, which required about 10 minutes on a
desktop computer.
Computing the false discovery rate
We compute the value of the epistasis statistic and its associated
nominal P-value for many thousands of site pairs. We therefore
need to quantify the fraction of false positives among the observed
nominally significant pairs [93]. Because the values of the epistasis
statistic for different site pairs are not independent, we estimate the
distribution of the number of false positives in the data through
bootstrap by designating 400 out of 104 permutations generated by
the procedure described above as ‘‘fake data sets’’. For each such
fake data set, which represents one draw from the null hypothesis,
we computed the number of nominally significant site pairs. This
allowed us to estimate the full distribution of the number of false
positives in the data. In particular, we recorded the expected
number of false positives in our data, which is typically referred to
as ‘‘false discovery rate’’ (FDR), and overall P-value for the total
number of positives actually observed.
Simulations without epistasis
To ensure that our method does not detect epistatic interactions
when there are none, we have performed detailed simulations of
sequence evolution along a phylogenetic tree, with independent
sites, as described in [25]. Briefly, the simulation algorithm takes as
input a phylogenetic tree with branch lengths equal to the number
of nucleotide substitutions and the nucleotide sequence at the root
of the tree; it outputs the nucleotide sequences at all internal and
terminal nodes. The sequence at a node is generated recursively,
given that the sequence at the parental node is already known,
using the following stochastic procedure. If the branch length
connecting the focal node to the parental node is l, then l
mutations are randomly distributed along the parental sequence
proportionally to the entries in the 4|3 nucleotide mutation
matrix and the codon-specific dN/dS values. We used the HA
phylogenetic tree to perform this simulation as well as to infer the
nucleotide mutation matrix and the codon-specific dN/dS values
[25]. Using this simulation algorithm, we generated 100
independent sequence data sets. On each of them, we performed
the analysis described above with 103 permutations, 100 of which
were considered ‘‘fake data sets’’.
Supporting Information
Figure S1 Dependence of the results for HA (subtype H3N2) on
the nominal P-value cutoff. Top panel shows the number of
nominally significant pairs (solid line: data; dashed line: expecta-
tion). Middle panel shows the P-value for the observed number of
significant pairs. Bottom panel shows the resulting FDR.
Found at: doi:10.1371/journal.pgen.1001301.s001 (0.02 MB EPS)
Figure S2 Dependence of the results for HA (subtype H3N2) on
the scale parameter t. Top panel shows the number of nominally
significant pairs. Bottom panel shows the resulting FDR. Colors
represent different nominal P-value cutoffs. The P-value for the
observed number of significant pairs always stays below 0.05 and
therefore not shown. The April 2009 version of the HA data set
was used to generate this figure (see ‘‘Materials and Methods’’).
Found at: doi:10.1371/journal.pgen.1001301.s002 (0.17 MB EPS)
Table S1 Lists of putatively epistatic pairs identified by our
analysis.
Found at: doi:10.1371/journal.pgen.1001301.s003 (0.21 MB
XLSX)
Table S2 Posterior probabilities of co-evolution inferred by the
BGM analysis (all branches). See Text S1 for details.
Found at: doi:10.1371/journal.pgen.1001301.s004 (5.92 MB
XLSX)
Table S3 Posterior probabilities of co-evolution inferred by the
BGM analysis (only interior branches). See Text S1 for details.
Found at: doi:10.1371/journal.pgen.1001301.s005 (1.36 MB
XLSX)
Table S4 Summary of epistasis analyses for 10 bootstrap
phylogenetic trees. ‘‘tree’’ is the bootstrap tree identifier; t is the
expected number of synonymous substitutions between a pair of
non-synonymous substitutions randomly drawn from the given
bootstrap tree; ‘‘sites’’ is the number of sites that experienced at
least 2 substitutions at the internal nodes of the tree; ‘‘pairs’’ is the
corresponding total number of ordered site pairs; ‘‘obs’’ is the
number of site pairs with the nominal P-value of 0.01 (in this
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level, and double asterisk indicates significance at 0.01 level);
‘‘FDR’’ is the false discovery rate and ‘‘overlap’’ is the number of
pairs that are significant at the 0.01 level with the given bootstrap
tree that are also in the list of pairs found in our original analysis;
percentages in the parentheses are computed with respect to the
333 nominally significant pairs found in our original analysis (see
Table 1 in the main text and Table S1).
Found at: doi:10.1371/journal.pgen.1001301.s006 (0.01 MB PDF)
Text S1 Supplementary information.
Found at: doi:10.1371/journal.pgen.1001301.s007 (0.15 MB PDF)
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